Latest Tiotropium bromide Stories
RIDGEFIELD, Conn., Nov. 3, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced that the U.S.
Data for the co-administration of Spiriva® HandiHaler® (tiotropium bromide inhalation powder) + Striverdi® Respimat® (olodaterol) Inhalation Spray presented at CHEST 2014 RIDGEFIELD,
The COPD Market Will Fracture with the Continuing Entry of LABA/LAMAs and Other Later-to-Market Bronchodilators, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct.
Approval Marks New Inhaler Choice for tiotropium RIDGEFIELD, Conn., Sept. 25, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S.
LifeScienceIndustryResearch.com adds “Spiriva (Asthma) – Forecast and Market Analysis to 2023” to its store.
Additionally, data from the WISDOM trial on stepwise withdrawal of ICS in COPD was also presented at ERS and simultaneously published in the New England Journal of Medicine RIDGEFIELD,
For U.S. Media Only RIDGEFIELD, Conn., Sept.
Sales of the LABA/LAMA Combination Drug Class are Expected to Grow Significantly Over the Next Six Months, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug.
For U.S. Media Only RIDGEFIELD, Conn., Aug. 19, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced that the U.S.
Committee Voted Based on Clinical Data from Eight Efficacy Trials RIDGEFIELD, Conn., Aug. 14, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.